594 related articles for article (PubMed ID: 25623736)
1. The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial.
Glenthøj LB; Fagerlund B; Randers L; Hjorthøj CR; Wenneberg C; Krakauer K; Vosgerau A; Gluud C; Medalia A; Roberts DL; Nordentoft M
Trials; 2015 Jan; 16():25. PubMed ID: 25623736
[TBL] [Abstract][Full Text] [Related]
2. Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial.
Glenthøj LB; Mariegaard LS; Fagerlund B; Jepsen JRM; Kristensen TD; Wenneberg C; Krakauer K; Medalia A; Roberts DL; Hjorthøj C; Nordentoft M
Schizophr Res; 2020 Oct; 224():151-158. PubMed ID: 32873460
[TBL] [Abstract][Full Text] [Related]
3. Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial.
Lewandowski KE; Sperry SH; Ongur D; Cohen BM; Norris LA; Keshavan MS
Trials; 2016 Mar; 17(1):136. PubMed ID: 26969299
[TBL] [Abstract][Full Text] [Related]
4. Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial.
Mediavilla R; Muñoz-Sanjose A; Rodriguez-Vega B; Bayon C; Palao A; Lahera G; Sanchez-Castro P; Roman E; Cebolla S; de Diego A; Pastor JM; Bravo-Ortiz MF
BMC Psychiatry; 2019 Jul; 19(1):233. PubMed ID: 31357965
[TBL] [Abstract][Full Text] [Related]
5. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
[TBL] [Abstract][Full Text] [Related]
6. [Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations].
Michel C; Toffel E; Schmidt SJ; Eliez S; Armando M; Solida-Tozzi A; Schultze-Lutter F; Debbané M
Encephale; 2017 May; 43(3):292-297. PubMed ID: 28347521
[TBL] [Abstract][Full Text] [Related]
7. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis.
Lam M; Lee J; Rapisarda A; See YM; Yang Z; Lee SA; Abdul-Rashid NA; Kraus M; Subramaniam M; Chong SA; Keefe RSE
JAMA Psychiatry; 2018 Sep; 75(9):929-939. PubMed ID: 30046827
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: The detection and evaluation of psychological therapy (DEPTh) trial.
Stain HJ; Bucci S; Baker AL; Carr V; Emsley R; Halpin S; Lewin T; Schall U; Clarke V; Crittenden K; Startup M
Schizophr Res; 2016 Oct; 176(2-3):212-219. PubMed ID: 27554197
[TBL] [Abstract][Full Text] [Related]
10. Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome.
Simon AE; Grädel M; Cattapan-Ludewig K; Gruber K; Ballinari P; Roth B; Umbricht D
Schizophr Res; 2012 Dec; 142(1-3):108-15. PubMed ID: 23025995
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive predictors of transition to psychosis: medium- to long-term findings from a sample at ultra-high risk for psychosis.
Lin A; Yung AR; Nelson B; Brewer WJ; Riley R; Simmons M; Pantelis C; Wood SJ
Psychol Med; 2013 Nov; 43(11):2349-60. PubMed ID: 23388122
[TBL] [Abstract][Full Text] [Related]
12. Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder.
O'Reilly K; Donohoe G; O'Sullivan D; Coyle C; Mullaney R; O'Connell P; Maddock C; Nulty A; O'Flynn P; O'Connell C; Kennedy HG
BMC Psychiatry; 2016 Jan; 16():5. PubMed ID: 26759167
[TBL] [Abstract][Full Text] [Related]
13. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
[TBL] [Abstract][Full Text] [Related]
15. Interview and questionnaire assessment of cognitive impairment in subjects at ultra-high risk for psychosis: Associations with cognitive test performance, psychosocial functioning, and positive symptoms.
Randers L; Fagerlund B; Jepsen JRM; Nordholm D; Krakauer K; Hjorthøj C; Glenthøj B; Nordentoft M
Psychiatry Res; 2020 Dec; 294():113498. PubMed ID: 33157481
[TBL] [Abstract][Full Text] [Related]
16. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
[TBL] [Abstract][Full Text] [Related]
17. Social cognition in clinical "at risk" for psychosis and first episode psychosis populations.
Thompson A; Papas A; Bartholomeusz C; Allott K; Amminger GP; Nelson B; Wood S; Yung A
Schizophr Res; 2012 Nov; 141(2-3):204-9. PubMed ID: 22959742
[TBL] [Abstract][Full Text] [Related]
18. Multifamily group psychoeducation and cognitive remediation for first-episode psychosis: a randomized controlled trial.
Breitborde NJ; Moreno FA; Mai-Dixon N; Peterson R; Durst L; Bernstein B; Byreddy S; McFarlane WR
BMC Psychiatry; 2011 Jan; 11():9. PubMed ID: 21226941
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
20. Integrative cognitive remediation for early psychosis: Results from a randomized controlled trial.
Vidarsdottir OG; Roberts DL; Twamley EW; Gudmundsdottir B; Sigurdsson E; Magnusdottir BB
Psychiatry Res; 2019 Mar; 273():690-698. PubMed ID: 31207854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
